Equities
Health CareMedical Equipment and Services
  • Price (JPY)316.00
  • Today's Change-24.00 / -7.06%
  • Shares traded2.21m
  • 1 Year change+74.59%
  • Beta1.4749
Data delayed at least 15 minutes, as of Mar 04 2026 01:17 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cyberdyne Inc is engaged in the research, development, manufacture, sale, and maintenance management related to Cybernics technology. The Company mainly uses human and the Internet of Things (IoH/IoT), robots, and artificial intelligence (AI) Cybernics technology to develop Cybernic systems. It develops the Cybernics treatment service business and the training service business that utilize Cybernics technology. The Company develops in various fields centered on HAL. HAL is a robot treatment device for the purpose of improving and regenerating the physical function of patients, a welfare device and life support device for the purpose of supporting independence, and a work support equipment. It can be used for various purposes by being worn and used by people. The Company is also involved in the productization of AI-equipped transport robots; cleaning robots; Cyin, which is used for communication with people with disabilities, and electrocardiography devices.

  • Revenue in JPY (TTM)4.11bn
  • Net income in JPY-3.00m
  • Incorporated2004
  • Employees211.00
  • Location
    Cyberdyne Inc2-2-1, Gakuen-MinamiTSUKUBA-SHI 305-0818JapanJPN
  • Phone+81 298553189
  • Fax+81 298553181
  • Websitehttps://www.cyberdyne.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kusurinomadoguchi Inc11.71bn2.59bn29.79bn484.0011.482.977.262.54228.38228.381,033.34882.360.6939--3.1924,186,230.0015.71--26.98--56.02--22.65------0.158--28.41--133.66------
Japan Tissue Engineering Co., Ltd.2.26bn-461.45m31.19bn204.00--5.92--13.81-11.36-11.3655.62129.740.36614.015.6311,071,850.00-7.48-4.87-8.33-5.5159.6259.41-20.43-15.896.59--0.00---2.341.23-278.32--0.5717--
Mizuho Medy Co Ltd11.26bn3.43bn36.54bn187.0010.671.969.903.25179.80179.80591.12980.860.52251.552.09--15.9027.7417.9633.0669.4474.5130.4336.696.46----37.29-1.4821.77-9.2262.0723.8782.06
Rion Co Ltd27.94bn2.98bn37.85bn1.01k12.681.148.691.35241.73241.732,267.252,682.200.71751.673.8927,692,170.007.656.578.727.6249.5350.1110.669.273.55--0.0028.398.365.377.829.9520.048.61
Nippon Care Supply Co., Ltd.34.10bn2.17bn39.60bn1.45k17.502.114.241.16139.36139.362,194.671,155.761.26101.8030.3523,453,350.008.007.3711.529.8036.4536.776.356.340.7615--0.091359.8011.9410.8813.573.7013.338.76
Win-Partners Co Ltd87.25bn2.14bn45.82bn630.0019.801.8118.990.525175.8575.853,098.48830.261.8321.984.45138,488,200.004.494.298.527.9211.9812.402.452.591.62--0.0068.005.644.759.981.5233.839.52
France Bed Holdings Co Ltd61.19bn2.72bn47.29bn1.81k18.991.165.940.772971.6571.651,627.811,177.550.90172.946.0633,769,870.004.014.195.055.6555.0053.374.454.781.951,504.330.244146.932.382.93-6.0014.15-2.507.39
Japan Eyewear Holdings Co Ltd17.99bn4.22bn47.59bn580.0011.422.807.942.64172.64172.64736.69704.930.47411.8016.5631,022,410.0011.13--12.75--79.15--23.48--0.785318.060.4966--23.20--80.15------
Medikit Co Ltd23.68bn3.09bn47.64bn989.0014.150.95249.412.01211.98211.981,621.483,149.960.46433.144.1023,940,550.006.075.706.726.3038.5539.3713.0713.845.33--0.000241.813.222.54-1.820.854821.5712.47
Cyberdyne Inc4.11bn-3.00m49.76bn211.00--1.9278.8512.11-0.0142-0.014219.46188.520.08331.607.7019,469,190.00-0.1034-1.36-0.1056-1.3861.0857.96-1.24-20.8013.94--0.0108--0.68919.5960.91---5.51--
Nagaileben Co Ltd16.69bn2.48bn54.83bn501.0022.131.4119.893.2880.6280.62544.001,263.590.38981.324.2033,321,640.005.786.906.137.4339.3743.3514.8418.6810.68--0.0067.123.48-0.097-8.81-5.8216.970.00
TAUNS Laboratories Inc14.92bn3.69bn57.89bn316.0016.023.3313.033.8833.9533.95139.96163.580.37210.91622.1347,226,430.009.20--13.12--64.90--24.72--0.948831.130.56--1.05--9.38------
Kitazato Corp10.98bn3.98bn58.96bn86.0014.803.0414.145.3799.6099.60274.45485.650.57231.838.92--20.77--21.73--66.93--36.29--14.33--0.00--2.20---4.63------
Shofu Inc38.97bn4.25bn67.14bn1.41k15.771.4712.391.72118.98118.981,092.321,279.850.75741.239.8127,577,490.008.287.279.278.2459.4558.4110.949.752.72--0.0032.9910.318.1918.1143.72-3.1930.39
Data as of Mar 04 2026. Currency figures normalised to Cyberdyne Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

2.63%Per cent of shares held by top holders
HolderShares% Held
Sawakami Asset Management, Inc.as of 31 Oct 20251.69m1.23%
Arcus Investment Ltd.as of 30 Sep 2025940.00k0.68%
Dimensional Fund Advisors LPas of 31 Jan 2026301.00k0.22%
Simplex Asset Management Co., Ltd.as of 05 Feb 2026273.70k0.20%
AcomeA SGR SpAas of 30 Jun 2025147.80k0.11%
Dimensional Fund Advisors Ltd.as of 30 Nov 202589.74k0.07%
SSgA Funds Management, Inc.as of 05 Feb 202678.60k0.06%
Azimut Capital Management SGR SpAas of 30 Dec 202564.00k0.05%
DFA Australia Ltd.as of 30 Nov 202524.01k0.02%
Daiwa Asset Management Co. Ltd.as of 30 Jun 20250.000.00%
More ▼
Data from 30 Sep 2025 - 19 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.